Cancer Biomarkers Market by Profiling Technology (Omic Technologies, Imaging Technologies, Immunoassays, and Cytogenetics Based Tests), Biomolecule (Genetic Biomarkers, Protein Biomarkers, and Glyco-biomarkers), Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Stomach Cancer, and Others), and Application (Diagnostics, Drug Discovery and Development, Prognostics,Risk Assessment, and Others): Global Opportunity Analysis and Industry Forecast, 2020–2027

Publisher: Allied Market Research
Publication Date: April, 2020
Healthcare / Medical Devices
Pages: 338
Delivery Format: PDF

Report Features
Table of Contents
Pricing
Methodology
Request Sample
Compare Offers
Make an Offer

The global cancer biomarkers market was valued at $10,944.08 million in 2019, and is projected to reach $26,979.50 million by 2027, registering a CAGR of 11.8% from 2020 to 2027.
Cancer biomarkers are traceable substances or molecules that indicate the existence of cancerous cells in the body. The prevention of cancer by diagnosing and analyzing various cancer biomarkers using different diagnostic techniques is a profound approach to obtain rapid results for treatment. There are various types of biomarkers such as proteins, peptides, antibodies, and nucleic acids. Presence of these biomarkers in tissues, urine, serum, blood, and other body fluids indicate an abnormal process or a disease. Various such biomarkers for cancer indications have been studied and are being used for diagnostics, prognostics, personalized medicines, and surrogate endpoints. The identification of different types of biomarkers is an integral part of various industries such as healthcare and pharmaceuticals.

The global cancer biomarkers market is expected to witness a significant growth during the forecast period due to increase in prevalence of various types of cancers such as breast, prostate, and lung cancer. In addition, surge in importance of biological & targeted drug therapies, technological advancements, accuracy, and reliability of cancer biomarkers also contribute toward the growth of the market. Moreover, increase in investments from governments and public & private sector toward R&D for cancer diagnostics have a positive impact on the market. However, high cost of drug development, threat of failure associated with cancer treatment, and unregulated government regulations and reimbursement policies hamper the market growth. In contrast, advancements of cancer research and significant unmet need for cancer diagnosis are anticipated to provide new opportunities for the cancer biomarkers market.
The market is segmented on the basis of profiling technology, biomolecule, cancer type, application, and region. By profiling technology, the market is bifurcated into omic technologies, imaging technologies, immunoassays, and cytogenetics-based tests. On the basis of biomolecules, the market is segmented into genetic biomarkers, protein biomarkers, and glyco-biomarkers. By biomolecule, the market is segmented into genetic biomarkers, protein biomarkers, and glyco-biomarkers. By cancer type, the market is segmented as breast cancer, lung cancer, prostate cancer, colorectal cancer, stomach cancer, and others. Based on application, the market is segmented across diagnostics, drug discovery and development, prognostics, risk assessment, and others. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

 The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
 It offers a quantitative analysis from 2019 to 2027, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.
 Comprehensive analysis of all geographical regions is provided to determine the prevailing opportunities.
 Key players are profiled, and their strategies are analyzed thoroughly to understand the competitive outlook of the global market.

KEY MARKET SEGMENTS
By Profiling Technology
• Omic Technologies
• Imaging Technologies
• Immunoassays
• Cytogenetics-based Tests
By Biomolecule
• Genetic Biomarkers
• Protein Biomarkers
• Glyco-biomarkers
By Cancer Type
• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Stomach Cancer
• Others
By Application
• Diagnostics
• Drug Discovery and Development
• Prognostics
• Risk Assessment
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Russia
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o Rest of Asia-Pacific
• LAMEA
o Brazil
o Saudi Arabia
o United Arab Emirates
o Rest of LAMEA

LIST OF KEY PLAYERS PROFILED IN THE REPORT

• Abbott Laboratories
• Bio-Rad Laboratories, Inc.
• Bristol-Myers Squibb Compnay
• Exact Sciences Corporation
• F.Hoffmann-La Roche Ltd.
• Merck KGaA
• PerkinElmer, Inc.
• Qiagen N.V.
• Siemens AG
• Thermo Fisher Scientific, Inc.

Offer Amount (Per user license)	Retail price (Per user license)
$ .00	$5,370

Are you looking for a Consultant?

Customers Who Viewed This Item Also Viewed